Conditions: Hepatitis C Virus
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 79
Healthy volunteers: no

Brief summary:
In this study, participants with hepatitis C virus (HCV) genotype 1 (GT1) who failed prior direct-acting antiviral (DAA) therapy will receive Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) to evaluate sustained virologic response (SVR) using this drug combination.

Detailed description:

Arms:
arm 1: Participants receive grazoprevir 100 mg once per day (QD), elbasvir 50 mg QD, and RBV 800 - 1400 mg total daily dose divided twice per day (based on body weight) for 12 weeks

Interventions: intervention 1: Grazoprevir (GZR) intervention 2: Elbasvir (EBR) intervention 3: Ribavirin (RBV)
Intervention descriptions: intervention 1: 100 mg oral tablet (total daily dose) intervention 2: 10 mg oral capsule (total daily dose = 5 capsules) intervention 3: 200 mg oral capsule (total daily dose = 4-7 capsules)

Protocol document: